Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy. - Campone, M.; Bondarenko, I.; Brincat, S.; Hotko, Y.; Munster, P. N.; Chmielowska, E.; Fumoleau, P.; Ward, R.; Bardy-Bouxin, N.; Leip, E.; Turnbull, K.; Zacharchuk, C.; et al. (Annals of Oncology, 2012)